Font size
WorksheetsQilu Palonosetron Hydrochloride Injection
Total questions: 10
Worksheet time: 2hrs 40mins
What is the strength of Qilu Palonosetron per 5 ml?
2.5 mg
25 mg
25 mcg
250 mcg
Qilu Palonosetron belongs to which pharmacological group of antiemetic?
5-HT3 antagonist
Neurokinin-1 antagonist
Dopamine antagonist
Benzodiazepine
Which of the following is NOT the indication of Qilu Palonosetron?
Chemotherapy-induced nausea and vomiting (CINV)
Prevention of CINV associated with HEC
Prevention of CINV associated with MEC
Prevention of CINV associated with LEC
Which of the following cytotoxic agent is NOT a moderately emetogenic chemotherapy?
Oxaliplatin
Carboplatin
Cisplatin
Irinotecan
Which of the following are the complications of CINV?
Dehydration & electrolyte imbalance
Poor quality of life & unable to perform normal daily activities
Refusal to continue chemotherapy
Physical & mental deterioration
Which of the following was withdrawn by the FDA because of the possibility of life-threatening cardiac arrhythmias due to QT-interval prolongation?
Domperidone
Granisetron
Dolasetron
Ondansetron
Choose the most accurate timeline of 5-HT3 antagonist injection being approved by FDA from the earliest to latest.
Palonosetron, Granisetron, Ondansetron, Dolasetron
Ondansetron, Granisetron, Dolasetron, Palonosetron
Dolasetron, Granisetron, Ondansetron, Palonosetron
Granisetron, Dolasetron, Ondansetron, Palonosetron
Which of the following regarding to palonosetron is/are correct?
It has the longest half-life among 5-HT3 antagonists
It is usually use alone as antiemetic for HEC
It is a 2nd generation 5-HT3 antagonists
It can be given intravenously and intramuscularly
Which of the following is NOT the benefit of palonosetron?
Longer half-life and stronger binding affinity than the first generation 5-HT3 antagonists
High risk of cardiac QT-interval prolongation
Single dose regime which improves patient compliance
None of the above
Which of the following regarding to the manufacturer is FALSE?
The company was established in 2015
The manufacturing site is in Haikou city, Hainan, China
The company name is Qilu Pharmaceutical (Hainan) Co., Ltd
Palonosetron is their first product registered in Medispec
